(AOF) – In a letter received on December 29, 2022, the company BVF Partners LP, acting on behalf of the funds it manages, declared to the AMF that it had crossed downwards, on December 23, 2022, the thresholds of 10 % of the capital and voting rights of the French biopharmaceutical company Erytech Pharma. BVF also declared that it held on behalf of said funds 2,299,301 Erytech Pharma shares representing the same number of voting rights, ie 7.41% of the capital and 7.07% of the voting rights of this company. This crossing of thresholds results from a sale of Erytech Pharma shares on the market.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.